Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial ; volume:15 ; number:1 ; day:25 ; month:11 ; year:2024 ; pages:1-9 ; date:12.2024
Nature Communications ; 15, Heft 1 (25.11.2024), 1-9, 12.2024
- Creator
-
Shiozawa, Manabu
Sunakawa, Yu
Watanabe, Takanori
Ota, Hirofumi
Yasui, Hisateru
Yabuno, Taichi
Tei, Mitsuyoshi
Kochi, Mitsugu
Manaka, Dai
Ohori, Hisatsugu
Yamaguchi, Tatsuro
Sagawa, Tamotsu
Kotaka, Masahito
Kubota, Yutaro
Sekikawa, Takashi
Nakamura, Masato
Takeuchi, Masahiro
Ichikawa, Wataru
Fujii, Masashi
Tsuji, Akihito
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-024-54460-2
- URN
-
urn:nbn:de:101:1-2502102147522.266583730028
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Shiozawa, Manabu
- Sunakawa, Yu
- Watanabe, Takanori
- Ota, Hirofumi
- Yasui, Hisateru
- Yabuno, Taichi
- Tei, Mitsuyoshi
- Kochi, Mitsugu
- Manaka, Dai
- Ohori, Hisatsugu
- Yamaguchi, Tatsuro
- Sagawa, Tamotsu
- Kotaka, Masahito
- Kubota, Yutaro
- Sekikawa, Takashi
- Nakamura, Masato
- Takeuchi, Masahiro
- Ichikawa, Wataru
- Fujii, Masashi
- Tsuji, Akihito
- SpringerLink (Online service)
Other Objects (12)
First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3
Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
Lobaplatin hyperthermic intraperitoneal chemotherapy plus cytoreduction and rechallenge using cetuximab for wild-type RAS peritoneal metastatic colon cancer: a case report and literature review
Deeper and deeper still : "Jephtha" / (Handel)
Controversies in the treatment of RAS wild-type metastatic colorectal cancer
First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3
Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
Lobaplatin hyperthermic intraperitoneal chemotherapy plus cytoreduction and rechallenge using cetuximab for wild-type RAS peritoneal metastatic colon cancer: a case report and literature review
Deeper and deeper still : "Jephtha" / (Handel)
Controversies in the treatment of RAS wild-type metastatic colorectal cancer
First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3
Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
Lobaplatin hyperthermic intraperitoneal chemotherapy plus cytoreduction and rechallenge using cetuximab for wild-type RAS peritoneal metastatic colon cancer: a case report and literature review
Deeper and deeper still : "Jephtha" / (Handel)